Prognostic Value of the Rockwood Clinical Frailty Score in Cardiogenic Shock

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Nov 14, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a tool called the Rockwood Clinical Frailty Score (CFS) to see how well it can predict the outcomes of patients experiencing cardiogenic shock, a serious condition where the heart cannot pump enough blood to meet the body's needs. The trial aims to simplify the assessment process for doctors, as current methods can be complicated and time-consuming, especially in emergency situations. The CFS is easy to use and relies on information that can be gathered from the patient or their family, making it a practical option for quickly determining a patient’s overall health and vulnerability.

To participate in this trial, individuals must be adults aged 18 or older who have been diagnosed with cardiogenic shock and are currently hospitalized in an Intensive Care Unit. They should not object to their medical data being used for research purposes. If you or a loved one meets these criteria, you can expect to contribute to important research that may help improve the treatment and care of patients with cardiogenic shock in the future. The trial is currently recruiting participants until September 2024, and it seeks to make a significant impact on how doctors assess and manage this critical condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patient (≥18 years)
• • Patient with cardiogenic shock according to ESC 2021 definition
• • Patient hospitalized from January 1, 2014 to September 1, 2024 in an Intensive Care Unit
• • Patients who do not object to the re-use of their data for the purposes of this research.
• Criteria Exclusion:
• • Patient having expressed his opposition to the re-use of his data for scientific research purposes.
• • Subject under court protection.
• • Subject under guardianship or curatorship.